| Title | Comparative cross over study of the effect of Latanoprost 0.005% eye drops and Timolol 0.5% eye drops in the intraocular pressure of patients suffering from primary open angle glaucoma: their effect on the respiratory system of patients with mild or moderate bronchial asthma | |
| Authors | Panagiotis Bournas¹, Dimitrios Kanellas¹, Thrassivoulos Dimopoulos¹, Emmanouel Vaikoussis¹ and Haris Karageorgiou²
1. Glaucoma Dept, Eye Clinic, General Hospital of Nikaia, Piraeus, Greece 2. Pharmacology Department, Medical School, Athens University, Athens, Greece |
|
| Citation | Bournas, P., Kanellas, D., Dimopoulos, T., Vaikoussis, E., Karageorgiou, H.: Comparative cross over study of the effect of Latanoprost 0.005% eye drops and Timolol 0.5% eye drops in the intraocular pressure of patients suffering from primary open angle glaucoma: their effect on the respiratory system of patients with mild or moderate bronchial asthma, Epitheorese Klin. Farmakol. Farmakokinet. 15(2): 97-103 (2001) | |
| Publication Date | Received for publication: 15 March 2001
Accepted for publication: 30 April 2001 |
|
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Latanoprost, timolol, intraocular pressure, human, glaucoma, bronchial asthma. | |
| Other Terms | review article | |
| Summary | The aim of this study is to investigate the effects of Latanoprost (L), Timolol (T) and their combination (L+T) in primary open angle glaucoma (POAG), and their possible effect, on the respiratory system of patients with mild or moderate asthma. Twenty seven patients were treated with (L) 0.005% for 3 months and, after a washout period, they were treated with (T) 0.5% for another 3 months (GROUP 1). Twenty six patients were treated with (T) 0.5% for 3 months and, after a washout period, (T) was replaced by (L) for 3 months as well (GROUP 2). Both groups were treated with the combination of (L+T) for 3 months. (L) reduced intraocular pressure (IOP) in either group by 8 mm Hg. (T) reduced the IOP by 6 mm Hg. (L+T) reduced the IOP by 9.5 mm Hg. (L) was more effective than (T) (P< 0.01) in either group 1 or 2. (L+T) was more effective than either drug alone reducing the IOP (P< 0.01). In order to examine the effects of these two medications in patients with mild or moderate bronchial asthma, when given topically in eye drops, 15 patients were studied (GROUP 3). No one was suffering from POAG. The FVC, FEV1, FEV1%, FEF50, FEF75, FEF25-75 values were measured. Then saline eye drops as placebo, were instillated and the above values were measured 15, 60 and 120 min. Later the same procedure was repeated for (L), (T) and (L+T) with a washout period of two weeks in between. It is concluded that (L) is rather safe for the treatment of POAG in patients with mild or moderate bronchial asthma because no respiratory changes were observed after each administration. Only topic effects as conjunctival hyperemia, smarting and iridal pigmentation were observed. Timolol, as it was expected, caused statistically significant reduction of the FVC, FEV1, FEV1%, FEF50, FEF75 and FEF25-75 values or indices. | |
| References | 1. Jaime L. et al: Cyclooxygenase-2 inhibitors: A New approach to the Therapy of Ocular Inflammation. Surv. Ophthalmol. 41, Febr. (1997)
2. Basu S., Sjoquist B., Stjernschantz J., Resul B.: Corneal permeability to and ocular metabolism of phenyl-substituted prostaglandin esters in vitro. Prostaglandin Leucot. Essent. Fatty Acids 50: 161-168 (1994) 3. Stjernschantz J., Selen G., Sjoquist B., and Resul B.: Preclinical pharmacology of Latanoprost, a phenyl-substituted RGF2a analogue. Adv. Prostaglandin Thomboxane Leukor. Res. 23: 513-518 (1995) 4. Karlsson M., Selen G., Stjernschantz. J., Resul B.: Receptor profile of PhXA41, a new phenyl-substituted prostaglandin ester. International Congress of Eye Research (ICER), Sept. Stresa, Italy, 1992 5. Selen G., Karlsonn M., Astin M., Stjernschantz J., Resul B.: Effects of PhXA34 and Phdh100A, two phenyl-substituted prostaglandin esters, on aqueous humor dynamics and microcirculation in the monkey eye. Association for Research in Vision and Ophthalmology (ARVO), Meeting Sarasota, Florida, USA, 1991 6. Toris C.B., Campras C.B., Yabionski M.E.: Effects of PhXA41, a new Prostaglandin F2a analogue on aqueous humor dynamics in human eyes. Ophthalmology 103: 1297-1304 (1993) 7. Bill A.: Conventional and uveoscleral drainage of aqueous humor in cynomolgus Monkey (Macaca irus) at normal and high intraocular pressures. Exp. Eye Res. 3: 45-54 (1996) 8. Zimmermann T.J.: Topical ophthalmic beta-blockers: A comparative review. J. Ocul. Pharmacol. 9: 373-384, (1993) 9. Pharmacia & Upjohn, data on file, latanoprost monograph, p. 55 10. Rulo A.H., Greve E.L, Hoyng P.F.: Additive effects of latanoprost, a prostaglandin F2a analogue, and timolol in patients with elevated intraocular pressure. Br. J. Ophthalmol. 73: 899-902 (1994) 11. Aim A., Stjernschantz J.: Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 102: 1743-1752 (1995) 12. Fristrom B.: A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension. Acta Ophthalmol. Scand. 74: 140-144(1996) 13. Bucci M.: Long-term efficacy and safety of Latanoprost in glaucoma patients inadequately controlled on timolol. 2nd International Glaucoma Symposium. Jerusalem, Israel, 15- 20 March, 1998 14. Hedner J.t Svedmyr N., Lumde H., Mandhal A.: The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate steroid asthma. Surv. Ophthalmol. 41 (Suppl 2): S111 -S115 (1997) |
|
| Relative Papers |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
| ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2001 – ANNUAL SUBSCRIPTION 2001 | |
| Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
| Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)
pharmakonpress[at]pharmakonpress[.]gr |
| Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)
pharmakonpress[at]pharmakonpress[.]gr |
|